Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Olinciguat







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Olinciguat
Clinical data
Other namesIW-1701
Legal status
Legal status
  • Investigational
Identifiers

  • (2R)-3,3,3-Trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide

CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H16F5N7O3
Molar mass509.397 g·mol−1
3D model (JSmol)

  • C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F

  • InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1

  • Key:YWQFJNWMWZMXRW-HXUWFJFHSA-N

Olinciguat (IW-1701) is a soluble guanylate cyclase stimulator that was in development for sickle cell anemia.[1][2][3] After receiving orphan drug status in 2018[4] and completing a phase II trial, its development for sickle cell anemia was discontinued in 2020.[5]

References

[edit]
  1. ^ Buys, E. S.; Zimmer, D. P.; Chickering, J.; Graul, R.; Chien, Y. T.; Profy, A.; Hadcock, J. R.; Masferrer, J. L.; Milne, G. T. (1 August 2018). "Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential". Nitric Oxide. 78: 72–80. doi:10.1016/j.niox.2018.05.009. ISSN 1089-8603. PMID 29859918. S2CID 44149174.
  • ^ Tchernychev, Boris; Li, Huihui; Lee, Sung-Kyun; Gao, Xin; Ramanarasimhaiah, Raghunath; Liu, Guang; Hall, Katherine C.; Bernier, Sylvie G.; Jones, Juli E.; Feil, Susanne; Feil, Robert; Buys, Emmanuel S.; Graul, Regina M.; Frenette, Paul S.; Masferrer, Jaime L. (September 2021). "Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease". British Journal of Pharmacology. 178 (17): 3463–3475. doi:10.1111/bph.15492. ISSN 1476-5381. PMC 8453770. PMID 33864386.
  • ^ Zimmer, Daniel P.; Shea, Courtney M.; Tobin, Jenny V.; Tchernychev, Boris; Germano, Peter; Sykes, Kristie; Banijamali, Ali R.; Jacobson, Sarah; Bernier, Sylvie G.; Sarno, Renee; Carvalho, Andrew; Chien, Yueh-tyng; Graul, Regina; Buys, Emmanuel S.; Jones, Juli E.; Wakefield, James D.; Price, Gavrielle M.; Chickering, Jennifer G.; Milne, G. Todd; Currie, Mark G.; Masferrer, Jaime L. (8 April 2020). "Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease". Frontiers in Pharmacology. 11: 419. doi:10.3389/fphar.2020.00419. ISSN 1663-9812. PMC 7156612. PMID 32322204.
  • ^ "Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease". investor.ironwoodpharma.com. Retrieved 8 November 2023.
  • ^ PhD, Joana Carvalho (20 October 2020). "Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease". sicklecellanemianews.com. Retrieved 8 November 2023.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Olinciguat&oldid=1205662230"
    Categories: 
    ●Sickle-cell disease
     ●Soluble guanylate cyclase stimulators
     ●Amides
     ●Trifluoromethyl compounds
     ●Fluoroarenes
     ●Oxazoles
     ●Pyrimidines
     ●Pyrazoles
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 10 February 2024, at 04:56 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki